IL146231A0 - Substituted phenylcylohexane carboxylic acid amides and their use as adenosine uptake inhibitors - Google Patents

Substituted phenylcylohexane carboxylic acid amides and their use as adenosine uptake inhibitors

Info

Publication number
IL146231A0
IL146231A0 IL14623100A IL14623100A IL146231A0 IL 146231 A0 IL146231 A0 IL 146231A0 IL 14623100 A IL14623100 A IL 14623100A IL 14623100 A IL14623100 A IL 14623100A IL 146231 A0 IL146231 A0 IL 146231A0
Authority
IL
Israel
Prior art keywords
phenylcylohexane
substituted
carboxylic acid
acid amides
uptake inhibitors
Prior art date
Application number
IL14623100A
Other languages
English (en)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL146231A0 publication Critical patent/IL146231A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
IL14623100A 1999-05-29 2000-05-16 Substituted phenylcylohexane carboxylic acid amides and their use as adenosine uptake inhibitors IL146231A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19924819A DE19924819A1 (de) 1999-05-29 1999-05-29 Substituierte Phenylcyclohexancarbonsäurebenzylamid (Adenosinaufnahmeinhibitoren)
PCT/EP2000/004431 WO2000073274A2 (de) 1999-05-29 2000-05-16 Substituierte phenylcyclohexancarbonsäureamide und ihre verwendung als adenosinaufnahme-inhibitoren

Publications (1)

Publication Number Publication Date
IL146231A0 true IL146231A0 (en) 2002-07-25

Family

ID=7909713

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14623100A IL146231A0 (en) 1999-05-29 2000-05-16 Substituted phenylcylohexane carboxylic acid amides and their use as adenosine uptake inhibitors

Country Status (25)

Country Link
US (1) US6984642B1 (xx)
EP (1) EP1187812B1 (xx)
JP (1) JP2003500474A (xx)
KR (1) KR20020000814A (xx)
CN (1) CN1165526C (xx)
AR (1) AR029639A1 (xx)
AT (1) ATE303995T1 (xx)
AU (1) AU766140B2 (xx)
BR (1) BR0011049A (xx)
CA (1) CA2375188A1 (xx)
CO (1) CO5170503A1 (xx)
DE (2) DE19924819A1 (xx)
DK (1) DK1187812T3 (xx)
ES (1) ES2248071T3 (xx)
GT (1) GT200000085A (xx)
HK (1) HK1047107B (xx)
HN (1) HN2000000078A (xx)
IL (1) IL146231A0 (xx)
MX (1) MXPA01012240A (xx)
PE (1) PE20010132A1 (xx)
PL (1) PL365960A1 (xx)
TR (1) TR200103398T2 (xx)
UY (1) UY26179A1 (xx)
WO (1) WO2000073274A2 (xx)
ZA (1) ZA200108894B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10150310A1 (de) * 2001-10-11 2003-04-24 Bayer Ag Substituierte Piperazincyclohexancarbonsäureamide und ihre Verwendung
KR100762858B1 (ko) * 2005-03-07 2007-10-02 김기완 Ｐｅ시트를 이용한 저수조의 방수 공법
KR100762857B1 (ko) * 2005-03-07 2007-10-02 김기완 Ｐｅ시트를 이용한 저수조의 방수 공법
KR100745024B1 (ko) * 2005-05-09 2007-08-01 김준 거푸집 수평조절장치
CN102159531A (zh) * 2008-07-16 2011-08-17 百时美施贵宝公司 趋化因子受体活性的环己烯基调节剂
EP2380595A1 (en) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2125285T3 (es) * 1992-07-31 1999-03-01 Bristol Myers Squibb Co Derivados inhibidores de la reabsorcion de adenosina de difenil-oxazoles, tiazoles e imidazoles.
DE4304455A1 (de) * 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
CN1202159A (zh) * 1995-09-22 1998-12-16 住友化学工业株式会社 吡嗪－2－酮衍生物,它们的应用及用于制备它们的中间体
US5723313A (en) * 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle

Also Published As

Publication number Publication date
AU766140B2 (en) 2003-10-09
HN2000000078A (es) 2001-02-02
JP2003500474A (ja) 2003-01-07
HK1047107A1 (en) 2003-02-07
ATE303995T1 (de) 2005-09-15
DE19924819A1 (de) 2000-11-30
ZA200108894B (en) 2003-01-29
WO2000073274A2 (de) 2000-12-07
WO2000073274A3 (de) 2001-04-19
BR0011049A (pt) 2002-03-19
CN1165526C (zh) 2004-09-08
GT200000085A (es) 2001-11-17
AU4405700A (en) 2000-12-18
HK1047107B (zh) 2005-05-20
US6984642B1 (en) 2006-01-10
CA2375188A1 (en) 2000-12-07
PE20010132A1 (es) 2001-04-12
DE50011122D1 (de) 2005-10-13
AR029639A1 (es) 2003-07-10
DK1187812T3 (da) 2005-12-12
KR20020000814A (ko) 2002-01-05
CN1353693A (zh) 2002-06-12
ES2248071T3 (es) 2006-03-16
MXPA01012240A (es) 2002-08-12
EP1187812A2 (de) 2002-03-20
CO5170503A1 (es) 2002-06-27
TR200103398T2 (tr) 2002-03-21
PL365960A1 (en) 2005-01-24
EP1187812B1 (de) 2005-09-07
UY26179A1 (es) 2000-12-29

Similar Documents

Publication Publication Date Title
HK1020724A1 (en) Aminothiophene carboxylic acid amides and the use thereof as phosphodiesterase inhibitors
GB2351077B (en) Improved acid corrosion inhibitor
IL144214A0 (en) Benzoheterocycles and their use as mek inhibitors
PL367196A1 (en) Carboxylic acid derivative and salt thereof
PL347884A1 (en) Substituted benzimidazoles and their use as parp inhibitors
HK1053124A1 (en) Substituted quinazoline derivatives and their use as inhibitors
HK1057214A1 (en) New mandelic acid derivatives and their use as throbin inhibitors
HUP0402550A3 (en) Esters and amides as ppar-alpha agonists
HUS1000019I1 (hu) Karbonsav-tartalmú szerek és növénytermesztésben való alkalmazásuk
ZA988469B (en) Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors
PL349769A1 (en) New amidinobenzylamine derivatives and their use as thrombin inhibitors
GB0017279D0 (en) Amides as cell adhesion inhibitors
HK1047274A1 (zh) 氨基苯甲酸衍生物
PL353214A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
IL146231A0 (en) Substituted phenylcylohexane carboxylic acid amides and their use as adenosine uptake inhibitors
IL146392A0 (en) Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect
IL154633A0 (en) Substituted phenylcyclohexane carboxylic acid amides and the use thereof
AU7437300A (en) Method to determine the susceptibility of scrapie in sheep
HK1039609A1 (zh) 甲氧基亞氨基苯基乙酰胺
PL357012A1 (en) Novel alpha-sulfin- and alpha-sulfonamino acid amides
SI1178958T1 (en) N-cyanomethyl amides as protease inhibitors
PL357715A1 (en) Alpha-sulfin- and alpha-sulfonamino acid amide derivatives
GB0011720D0 (en) Hydroxamic and carboxylic acid derivatives
GB0029393D0 (en) Hydroxamic and carboxylic acid derivatives
SI1214302T1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors